Drug intelligence / Profile preview

CORT125324

Development stage: Unknown
Lead developer: Corcept Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

CORT125324 is a **selective glucocorticoid receptor antagonist** developed as an investigational small molecule. Its primary mechanism is antagonism of the glucocorticoid receptor, aiming to block excessive cortisol signaling. It is being studied for potential therapeutic use in conditions such as Cushing's syndrome due to its selectivity for the glucocorticoid receptor and potential to avoid off-target effects associated with less selective antagonists. CORT125324 is related to but distinct from relacorilant (CORT125134), with enhanced selectivity and potency demonstrated in preclinical studies.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on CORT125324.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CORT125324.

Explore the full profile